AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Utilization Patterns of Pulmicort in Real Life Practice
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 260
- Registration Number
- NCT00660569
- Locations
- 🇪🇸
Research Site, Toledo, Spain
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 276
- Registration Number
- NCT00660660
- Locations
- 🇺🇸
Research Site, Bellevue, Washington, United States
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Completed
- Conditions
- DiabetesCoronary Heart DiseasePeripheral Vascular DiseaseHypercholesterolemiaCerebrovascular Accident
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00660764
Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2009-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1018
- Registration Number
- NCT00660712
- Locations
- 🇹🇷
Research Site, Trabzon, Turkey
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
Phase 3
Completed
- Conditions
- Hay FeverRhinitis, Allergic, Seasonal
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00659594
- Locations
- 🇨🇦
Altana/Nycomed, Mississauga, Ontario, Canada
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, PerennialHay Fever
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00658918
- Locations
- 🇺🇸
Altana/Nycomed, Little Rock, Arkansas, United States
Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, SeasonalHay Fever
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 420
- Registration Number
- NCT00659503
- Locations
- 🇨🇦
Altana/Nycomed, Kingston, Ontario, Canada
To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 418
- Registration Number
- NCT00659750
- Locations
- 🇺🇸
Altana/Nycomed, Madison, Wisconsin, United States
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 106
- Registration Number
- NCT00659048
- Locations
- 🇺🇸
Altana/Nycomed, San Antonio, Texas, United States
Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1940
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 151
- Registration Number
- NCT00659490
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath